Colorectal cancer (CRC) remains a major global health burden, ranking as the third most commonly diagnosed cancer and the second leading cause of cancer-related death worldwide. Despite its prevalence, CRC is one of the most preventable and treatable malignancies when detected early. Screening plays a crucial role in both primary prevention by identifying and removing precancerous polyps and secondary prevention through early detection, significantly improving survival. This chapter provides an overview of the main CRC screening methods, including colonoscopy, fecal immunochemical tests (FIT), stool DNA tests, flexible sigmoidoscopy, CT colonography, and serum tumor biomarkers. Each modality is analyzed by sensitivity, specificity, accessibility, cost, and effectiveness. The importance of individualized strategies based on risk factors such as age, family history, genetic syndromes, and lifestyle is emphasized. Attention is given to disparities in global screening uptake, with examples from national programs in the United Kingdom, the Netherlands, the United States, and Romania, where I work. Barriers to participation such as limited healthcare access, cultural stigma, and lack of awareness are identified, along with evidence-based strategies to improve engagement. The chapter also highlights innovations such as artificial intelligence, digital health tools, and microbiome analysis, which may transform CRC screening in the future. Finally, it underscores the critical role of healthcare professionals and community involvement in increasing adherence and ensuring equitable access. Effective CRC screening is not only a clinical necessity but a public health priority with potential to save lives and reduce costs.